NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=123047&from=4CLASS PERIOD: T ...

Please check back later to see all of our exciting changes. ...

NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX). Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=122789&from=3 CLASS P ...

Extending Company's leadership position in autoimmune CAR T with prioritized indication strategy; pivoting to late-stage development and commercialization First-to-market opportunity with KYV-101 in stiff person syndrome; 40% enrolled in pivotal Phase 2 trial with first BLA filing targeted for 2026; fast-follow indications in myasthenia gravis and lupus nephritis Efficiently expanding into broader autoimmune indications and increasing patient reach with KYV-102 using whole blood rapid manufacturing Cash run ...

NEW YORK, Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=121991&from=4CLASS PERIOD: T ...

Core Viewpoint - A securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. for allegedly making materially false and misleading statements in connection with its February 8, 2024 IPO [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Kyverna common stock during its IPO [1]. - The lead plaintiff deadline for the lawsuit is set for February 7, 2025 [1][3]. - The complaint alleges that Kyverna failed to disclose adverse data related to one of its clinical trials at the time of the IPO [2]. Group 2: Lead Plaintiff Process - Investors may seek to be appointed as a lead plaintiff representative of the class by the deadline or may choose to remain absent [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial interest in the case [3]. Group 3: Law Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

Core Viewpoint - A class action has been filed against Kyverna Therapeutics, Inc. for allegedly providing misleading information in its IPO documents, leading to a significant decline in share price [1][2][3]. Group 1: Allegations and Legal Action - The complaint claims that the Offering Documents for Kyverna's IPO were negligently prepared and did not comply with regulatory standards [2]. - Specific statements in the Offering Documents regarding trial results were deemed false and misleading due to the omission of adverse data [2]. - By the time the action commenced, Kyverna's shares had dropped to $3.92, representing an over 82% decline from the IPO offering price [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their applications by February 7, 2025 [4]. - Participation in the class action is not mandatory for recovery; shareholders can remain absent class members if they choose [4]. Group 3: Company Background - Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases [1].

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company's of ...

BENSALEM, Pa., Jan. 6, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ: KYTX).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN KYVERNA THERAPEUTICS, INC. (KYTX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE FEBRUARY 7, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact t ...

NEW YORK, Jan. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=120456&from=4CLASS PERIOD: Th ...